Drug Profile
Research programme: anti-chitinase-like monoclonal antibodies - AstraZeneca
Alternative Names: Anti-AMCase monoclonal antibodies - AstraZeneca ; Anti-chitinase 3-like protein 1 monoclonal antibodies - AstraZeneca; Anti-chitinase monoclonal antibodies - AstraZeneca; Anti-hcGP-39 monclonal antibodies - AstraZeneca; Anti-YKL-40 monoclonal antibodies - AstraZenecaLatest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Parenteral)